关于胡超红博士任命情况 - 胡超红博士被任命为和黄医药独立非执行董事兼技术委员会成员2024年11月21日起生效 [1] - 胡博士有超20年治疗性抗体、抗体 - 药物偶联物和疫苗开发经验具备从早期发现到临床开发和商业化的专业知识有成功商业发展和战略合作伙伴关系经验 [2] - 胡博士58岁现任D Biotherapeutics, LLC首席运营官等职位之前在多家公司任职 [3] - 胡博士拥有武汉大学理学学士学位和中科院生物物理所分子生物学博士学位 [4] - 胡博士任期到下一届年度股东大会结束之后可连任董事费每年76000美元技术委员会成员费每年8000美元 [5][7] - 胡博士除已披露信息外无其他需披露信息 [9] 关于和黄医药公司情况 - 和黄医药是创新型商业化阶段生物制药公司致力于癌症和免疫疾病靶向和免疫疗法的发现全球开发和商业化约有5000名员工其中肿瘤/免疫学团队约1800人 [10]

SAN DIEGO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Paycor HCM, Inc. (NASDAQ: PYCR), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. What if I purchased PYCR securities? If you purchased securities and suffered losses on your investment ...

HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies of compounds discovered by HUTCHMED will be presented at the American Society of Hematology (“ASH”) Annual Meeting taking place on December 7-10, 2024 in San Diego, USA, and the European Society for Medical Oncology (“ESMO”) Asia ...

文章核心观点 - 公司HUTCHMED与合作伙伴Takeda合作开发的抗肿瘤药物fruquintinib在全球范围内获批上市,并在美国、欧洲等主要市场取得了超过2亿美元的销售额,触发了HUTCHMED获得2000万美元的里程碑付款[1][2][3] - 公司表示这一销售里程碑的实现证明了Takeda在全球品牌推广方面的实力,也反映了fruquintinib的临床获益和公司全球合作战略的成功[3] - 公司表示将利用这笔里程碑付款来拓展fruquintinib在新适应症的使用,并强调了公司在全球范围内推进广泛管线的策略[3] 行业概况 - 结直肠癌是全球第三大常见癌症,每年新发病例超过190万例,死亡病例超过90万例[4] - 在美国,2024年预计将有15.3万新发病例,5.3万人死于该病[4] - 在欧洲,2022年结直肠癌是第二大常见癌症,新发病例约53.8万例,死亡病例约24.8万例[4] - 在日本,2022年结直肠癌是最常见的癌症,新发病例约14.6万例,死亡病例约6万例[4] - 早期结直肠癌可通过手术切除,但转移性结直肠癌仍是一个高度未满足的需求领域,预后较差,治疗选择有限[4] - 部分转移性结直肠癌患者可从基于分子特征的个体化治疗中获益,但大多数患者的肿瘤并未携带可操作的突变[4] fruquintinib获批情况 - fruquintinib的全球监管申请基于两项大型随机对照III期临床试验的数据,包括全球多中心FRESCO-2试验和在中国开展的FRESCO试验,共734名患者接受了fruquintinib治疗,安全性良好[5] - FRESCO-2试验结果于2023年6月发表在《柳叶刀》杂志上,FRESCO试验结果发表在《美国医学会杂志》上[5] - 在中国大陆、香港和澳门,fruquintinib由HUTCHMED和礼来公司联合销售,商品名为ELUNATE,自2020年1月起纳入中国国家医保目录[5] - 自上市以来,已有超过10万名结直肠癌患者使用过fruquintinib[5] fruquintinib产品特点 - fruquintinib是一种选择性口服VEGF受体(VEGFR-1、-2和-3)抑制剂,VEGFR抑制剂在抑制肿瘤血管生成中发挥关键作用[6] - fruquintinib的设计目标是具有更强的选择性,可限制非靶标激酶活性,从而实现持续的靶标抑制和灵活的联合用药潜力[6] HUTCHMED公司概况 - HUTCHMED是一家创新型商业化生物制药公司,致力于肿瘤和免疫疾病靶向治疗和免疫治疗的发现、全球开发和商业化[7] - 公司拥有约5000名员工,其中约1800人专注于肿瘤/免疫领域[7] - 公司自成立以来一直专注于将自主发现的候选药物推向全球市场,已有3款药物在中国获批上市,其中1款还获得了美国、欧洲和日本的批准[7]

Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling Initial Data from Cohort 1 to be Reported in December 2024 Highlights Recently Presented Insights on Pediatric MYBPC3-associated HCM Disease Burden SOUTH SAN FRANCISCO, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that add ...

文章核心观点 - 新数据显示口服治疗组合能有效解决EGFR突变肺癌患者对EGFR靶向治疗产生的MET驱动耐药 [1][2] - MET是这类患者耐药的常见生物标志物 [2] - TAGRISSO®(奥希替尼)联合ORPATHYS®(沙伐替尼)在EGFR突变肺癌患者中表现出高的临床意义和持久的客观缓解率 [1][3] 公司和行业概况 - 肺癌是全球最常见的癌症之一,每年约有240万新诊断病例 [5] - EGFR突变型肺癌患者占美欧10-15%,亚洲30-40% [5] - MET过表达和/或扩增是EGFR靶向治疗耐药的主要机制,15-50%的奥希替尼治疗后进展患者存在MET异常 [5] SAVANNAH试验 - SAVANNAH是一项全球性、随机的II期临床试验,评估ORPATHYS®联合TAGRISSO®在EGFR突变、MET过表达和/或扩增的晚期肺癌患者中的疗效 [6] - 该试验共入组超过360名患者,主要终点为客观缓解率 [6] TAGRISSO®和ORPATHYS® - TAGRISSO®是一种第三代不可逆EGFR酪氨酸激酶抑制剂,已广泛用于EGFR突变肺癌的治疗 [7] - ORPATHYS®是一种口服、高选择性的MET酪氨酸激酶抑制剂,已在中国获批用于治疗MET外显子14跳跃突变的肺癌 [8]

Shares of HUTCHMED (China) Ltd (HCM, Financial) surged 2.90% in mid-day trading on Oct 2. The stock reached an intraday high of $21.10, before settling at $20.58, up from its previous close of $20.00. This places HCM 6.11% below its 52-week high of $21.92 and 72.44% above its 52-week low of $11.93. Trading volume was 210,051 shares, 216.8% of the average daily volume of 96,867. Wall Street Analysts Forecast Based on the one-year price targets offered by 12 analysts, the average target price for HUTCHMED (Ch ...

Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population  Study design intended to enable supplemental new drug application (sNDA) with a broad label in both obstructive and non-obstructive HCM THE WOODLANDS, Texas, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will unveil study design details of SONATA-HCM, the company’s Phase 3 clinica ...

— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — — Fruquintinib already approved in several regions including the United States, Europe and China — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that its partner Takeda (TSE:​4502/​NYSE:​TAK) has received approval from the Japanese Ministry of Health, Labour and ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the 2024 World Conference on Lung Cancer (“WCLC24”) in San Diego, USA, and the European Society for Medical Oncology (“ESMO”) Congress 2024, taking place in Barcelona, Spain. Results from the FLOWERS study, a prospective, two-arm, randomized, mul ...